COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,757 Articles (22,502 medRxiv, 8,255 bioRxiv)

Most recent first Previous |  Page 1520: Articles 15191-15200  | Next

Comparing Expression of OAS-RNaseL Pathway-Related Genes in SARS-CoV-2 and Similar Viruses
Chakravarty, N., Edillor, P. A., Huang, A. P., Torres, G. A., Usmani, M. T., Kadandale, P.
10.1101/2021.04.29.442063 — Posted: 2021-04-30
Single-tube collection and nucleic acid analysis of clinical samples: a rapid approach for SARS-CoV-2 saliva testing
Cole, K. H., Bouin, A., Ruiz, C., Semler, B. L., Inlay, M. A., Luptak, A.
10.1101/2021.04.29.21256345 — Posted: 2021-04-30
Limited within-host diversity and tight transmission bottlenecks limit SARS-CoV-2 evolution in acutely infected individuals
Braun, K., Moreno, G. K., Wagner, C., Accola, M. A., Rehrauer, W. M., Baker, D. A., Koelle, K., O'Connor, D., Bedford, T., Friedrich, T., Moncla, L. H.
10.1101/2021.04.30.440988 — Posted: 2021-04-30
SARS-CoV-2 sculpts the immune system to induce sustained virus-specific naïve-like and memory B cell responses
de Campos-Mata, L., Tejedor Vaquero, S., Tacho-Pinot, R., Pinero, J., Grasset, E. K., Arrieta Aldea, I., Rodrigo Melero, N., Carolis, C., Horcajada, J. P., Cerutti, A., Villar-Garcia, J., Magri, G.
10.1101/2021.04.29.21256002 — Posted: 2021-04-30
COMPARISON OF PERFORMANCE CHARACTERISTICS BETWEEN LATERAL FLOW, ELISA AND ELECTROCHEMILUMINESCENCE IMMUNOASSAYS FOR THE DETECTION OF SARS-COV-2 ANTIBODIES AMONG HEALTHCARE WORKERS
M R, S., Govindan, V., H H, S., V T, V., K, P., K L, R.
10.1101/2021.04.29.21256260 — Posted: 2021-04-30
Racial and ethnic disparities for SARS-CoV-2 positivity in the United States: a generalizing pandemic
Ferguson, J. M., Justice, A. C., Osborne, T. F., Abdel Magid, H. S., Purnell, A. L., Rentsch, C. T.
10.1101/2021.04.27.21256215 — Posted: 2021-04-30
National hospital readiness for COVID-19 in Lesotho: Evidence for oxygen ecosystem strengthening
Sanders, J. E., Chakare, T., Mapota-Masoabi, L., Ranyali-Otubanjo, M., Ramokhele, M. M., Rozario, A., McCollum, E. D.
10.1101/2021.04.27.21256199 — Posted: 2021-04-30
SARS-CoV-2 serological findings and exposure risk among employees in school and retail after first and second wave COVID-19 pandemic in Oslo, Norway: a cohort study
Moe, A.-M. G., Eriksen, M., Schjolberg, T., Haugen, F.
10.1101/2021.04.27.21256214 — Posted: 2021-04-30
Objective and Subjective COVID-19 Vaccine Reactogenicity by Age and Vaccine Manufacturer
Presby, D., Capodilupo, E.
10.1101/2021.04.29.21256255 — Posted: 2021-04-30
Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for COVID-19
Corchado-Garcia, J., Puyraimond-Zemmour, D., Hughes, T., Cristea-Platon, T., Lenehan, P., Pawlowski, C., Bade, S., OHoro, J. C., Gores, G. J., Williams, A. W., Badley, A. D., Halamka, J., Virk, A., Swift, M. D., Wagner, T., Soundararajan, V.
10.1101/2021.04.27.21256193 — Posted: 2021-04-30 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).